TABLE 5

Studies reporting prevalences of colistin resistance among K. pneumoniae clinical isolatesd

Study type and periodCountrySettingTest methodTotal no. of isolatesCarbapenemase producers (no. [%])Polymyxin-resistant isolates (no. [%])Reference(s)
Studies reporting colistin resistance rates among overall clinical isolates
    2006–2009WorldwideWorldwide surveillanceBMD9,774NA(1.5)183
    2007–2008CanadaNationalBMD515NA15 (2.9)184
    2013–2014United StatesMulticenterBMD1,205NA(4)185
    2006–2007South KoreaMulticenter (9 hospitals)BMD221a15 (13.3)24 (10.9)b206
    2004–2005SingaporeSingle centerAgar dilution16NA1 (6)207
Studies reporting colistin resistance rates among CR-KP isolates
    2008–2011CanadaMulticenterEtest3030 (100)2 (6.7)184, 186
    2013–2014United StatesMulticenterBMD6969 (100)(18)c185
    2003–2004United StatesMulticenterBMD or agar dilution9696 (100)(9)187
    2010–2013GreeceSingle center (only ICU)Vitek2, Etest9292 (100)20 (21.7)202
    2010GreeceSingle centerVitek2, Etest120120 (100)25 (20.8)203
    2014ItalySingle center (only ICU)Vitek2, Etest214214 (100)47 (21.9)199
    2013ItalySingle center (only ICU)BMD2524 (100)6 (24.0)200
    2013–2014ItalyNationalBMD178178 (100)76 (43)201
    2010–2011ItalyMulticenter (9 hospitals)Vitek2, BMD9797 (100)35 (36.1)68
    2010–2012SpainHospitalAgar dilution7979 (100)18 (22.8)204
    2014FranceNationalBMD561561 (100)35 (6.2)205
    2012–2013TurkeySingle centerVitek2, Etest3736 (98)(2.7)245
    2006–2007IsraelSingle center?8888 (100)(4.5)246
    2009–2010ChinaSingle centerAgar dilution6868 (100)3 (4.4)208
    2012TaiwanNationalSensititre24755 (22.3)(12.1)209
  • a Isolated from blood samples.

  • b Number of colistin-resistant isolates according to EUCAST breakpoints.

  • c Eighteen percent colistin resistance among 4 E. coli and 69 K. pneumoniae isolates harboring carbapenemases.

  • d NA, not applicable.